AstraZeneca PLC (AZN)vsCorMedix Inc (CRMD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CRMD
CorMedix Inc
$7.48
-1.19%
HEALTHCARE · Cap: $586.55M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 18744% more annual revenue ($58.74B vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs 17.4%. CRMD trades at a lower P/E of 3.6x. CRMD earns a higher WallStSmart Score of 70/100 (B-).
AZN
Buy64
out of 100
Grade: C+
CRMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for CRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
Revenue surging 312.1% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Earnings declined 28.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%. Revenue growth of 312.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CRMD
The primary concerns for CRMD are Market Cap, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a value stock while CRMD is a growth play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.41 — expect wider price swings.
CRMD is growing revenue faster at 312.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 64/100), backed by strong 52.3% margins and 312.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?